Pernix Therapeutics Announces Restructuring and Integration of the Pernix and Hawthorn Sales Forces
News Jan 25, 2013
The sales force will remain focused on Pediatrics, Primary Care and Gastroenterology.
The Company today also announced that David Becker will resign his position as Chief Financial Officer, due to personal reasons, effective March 31, 2013. The Company has started a search to identify a new Chief Financial Officer. Upon naming a successor, Mr. Becker will serve the Company as a consultant in several areas, including manufacturing, over-the-counter products, and business development.
Cooper Collins, President and CEO of Pernix, said, “We closed the acquisition of Cypress and Hawthorn at the end of December, and we are rapidly making progress in the implementation of our integration plans. In addition, we appreciate the service that David has provided the Company, which included building our OTC product group and completing several key business development transactions that have broadened the scope of our business and expanded our portfolio of branded and generic products.”
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE
Concept Life Sciences Appoints New Group Head of ToxicologyNews
Appointment supports growth of the Company and expansion of expertise in integrated drug discovery and development.READ MORE
Gyros Protein Technologies Signs Distribution Agreement with Euro DiagnosticaNews
Gyros Protein Technologies becomes distributor of iLite cell-based reporter gene assays for drug development.READ MORE